ArticleTransplantation2011
The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction.
Article in Transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- The viability of ABO-incompatible kidney transplants: a single-center cohort in China.Frontiers in immunology · 2026Pooled it
- Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis.International urology and nephrology · 2014Pooled it
- The history and future landscape for paediatric ABO incompatible kidney transplantation.Pediatric nephrology (Berlin, Germany) · 2026Review
- Case Report: sustained five-year remission in eosinophilic granulomatosis with polyangiitis with intestinal perforation after surgery and rituximab-based therapy without glucocorticoid escalation.Frontiers in immunology · 2026Article
- Clinical significance of persistent C4d deposition on sequential protocol biopsies in ABO-incompatible kidney transplantation.Frontiers in nephrology · 2026Article
- Article
- Novel Flow Cytometry Method Detecting Complement C1q Bound to Blood Type A/B IgG Antibody for Preventing Severe Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.Antibodies (Basel, Switzerland) · 2024Article
- Incidence of postoperative cytomegalovirus and BK-polyoma virus infections and graft loss in ABO-incompatible renal transplant recipients: a multicenter retrospective study.International urology and nephrology · 2024Article
- Experiences of performing ABO-incompatible kidney transplantation in Bangladesh.Korean journal of transplantation · 2022Article
- Use of immunoadsorption columns in ABO-incompatible renal transplantation: A prospective study at a tertiary care center in India.Medical journal, Armed Forces India · 2021Article
- ABO-incompatible pediatric kidney transplantation without antibody removal.Pediatric nephrology (Berlin, Germany) · 2020Article
- Association Between Peripheral Blood CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients.Transplantation direct · 2019Article
- Observational
- Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians.Journal of transplantation · 2018Review
- Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.Clinical and experimental nephrology · 2017Article
- Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts.Xenotransplantation · 2017Article
- Ongoing higher infection rate in ABO-incompatible kidney transplant recipient: is it a serious problem? A single-center experience.Annals of surgical treatment and research · 2016Article
- Strategies to overcome the ABO barrier in kidney transplantation.Nature reviews. Nephrology · 2015Review
- ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange.Journal of clinical apheresis · 2015Article
- Current progress in ABO-incompatible kidney transplantation.Kidney research and clinical practice · 2015Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2002, we introduced the anti-CD20 chimeric antibody, rituximab, for ABO-incompatible kidney transplantation (ABO-IKT). Here, we report the 5-year outcome obtained using rituximab as part of the preoperative regimen for ABO-IKT.
methodsBetween January 2002 and December 2008, 408 patients underwent living-related kidney transplantation at our department. The patients were divided into three groups: group A (n=280), ABO-compatible kidney transplantation (ABO-CKT); group B (n=63), ABO-IKT without rituximab induction; and group C (n=50), ABO-IKT with rituximab induction. Basic immunosuppression was the same in all three groups except for the use of rituximab, which was administered at 100 mg (n=6), 200 mg (n=26), and 500 to 1000 mg (n=18).
resultsThe graft survival rates in groups A, B, and C were 99.2%, 96.8%, and 100% at 1 year, 93.8%, 94.9%, and 100% at 3 years, and 88.4%, 90.3%, and 100% at 5 years after transplantation, respectively. Serum creatinine levels in the three groups were not different at 1, 3, and 5 years after transplantation. The numbers of episodes of acute antibody-mediated rejection in groups A, B, and C were 7 (2.5%), 10 (15.9%), and 2 (4.0%), respectively (P=0.651), and acute cellular rejection was observed in 40 (14.3%), 6 (9.5%), and 2 (4.0%) patients, respectively (P=0.0957). There was no increased risk of cytomegalovirus infection in group C.
conclusionsIn the long term, inclusion of rituximab in the preoperative regimen yielded an even better outcome than that of ABO-CKT and rituximab-untreated ABO-IKT, without any increase in the risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.